Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Silence Therapeutics (SLN) Shares Outstanding (2020 - 2025)

Silence Therapeutics' Shares Outstanding history spans 6 years, with the latest figure at $47.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 66.66% to $47.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.2 million, a 66.66% decrease, with the full-year FY2025 number at $47.2 million, down 66.66% from a year prior.
  • Shares Outstanding hit $141.7 million in Q4 2025 for Silence Therapeutics, roughly flat from $141.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for SLN hit a ceiling of $184.0 million in Q3 2024 and a floor of $42.2 million in Q4 2022.
  • Historically, Shares Outstanding has averaged $141.6 million across 5 years, with a median of $141.7 million in 2025.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 249.95% in 2023 and later plummeted 74.33% in 2025.
  • Tracing SLN's Shares Outstanding over 5 years: stood at $121.0 million in 2021, then crashed by 65.17% to $42.2 million in 2022, then skyrocketed by 249.95% to $147.5 million in 2023, then decreased by 3.95% to $141.7 million in 2024, then crashed by 66.66% to $47.2 million in 2025.
  • Business Quant data shows Shares Outstanding for SLN at $47.2 million in Q4 2025, $47.2 million in Q3 2025, and $141.7 million in Q2 2025.